Intervene before overt hepatic encephalopathy (OHE) strikes again

What can you do to reduce your patients'
risk of recurrence?

 

AASLD/EASL
Guidelines

 
 

Look up insurance
coverage

 
 

Instant Savings
Card available

 

HE = hepatic encephalopathy

AASLD = American Association for the Study of Liver Diseases

EASL = European Association for the Study of the Liver

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.